Name:	akca_AnnualWorldwideNetSalesThresholdRequiredForSubsequentMilestonePaymentsToBePaidInCash
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Value of commercial inotersen inventory held by Ionis, which will be paid in cash and recorded as a reduction of additional paid in capital.

No definition available.

Name:	akca_CommercialInventoryAcquired
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

No definition available.

Name:	akca_DevelopmentCommercializationCollaborationAndLicenseAgreementAbstract
Namespace Prefix:	akca_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Liability for costs incurred and expensed by Ionis Pharmaceuticals, Inc. prior to the closing of the TTR license agreement.

No definition available.

Name:	akca_LiabilityForCostsIncurredByRelatedPartyPriorToClosingOfAgreement
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The maximum amount of payments payable for milestones under the collaboration agreement.

No definition available.

Name:	akca_MaximumAmountOfPaymentsPayableForMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The period of time required for the Company to provide written notice requesting termination of the License Agreement with Ionis Pharmaceuticals, Inc. (Ionis), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_NoticePeriodForTerminationOfAgreement
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The number of sales milestones under the agreement.

No definition available.

Name:	akca_NumberOfSalesMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

The percentage of profits and losses from the development and commercialization of inotersen paid to Ionis through the end of the quarter in which the first commercial sale of AKCEA-TTR-LRx occurs.

No definition available.

Name:	akca_PercentageOfProfitsAndLossesFromDevelopmentAndCommercializationOfDrug1PaidTier1
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The percentage of profits and losses from the development and commercialization of inotersen paid to Ionis on the first day of the first quarter after the first commercial sale of AKCEA-TTR-LRx occurs.

No definition available.

Name:	akca_PercentageOfProfitsAndLossesFromDevelopmentAndCommercializationOfDrug1PaidTier2
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The percentage of profits and losses from the development and commercialization of inotersen retained by the Company through the end of the quarter in which the first commercial sale of AKCEA-TTR-LRx occurs.

No definition available.

Name:	akca_PercentageOfProfitsAndLossesFromDevelopmentAndCommercializationOfDrug1RetainedTier1
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The percentage of profits and losses from the development and commercialization of inotersen retained by the Company on the first day of the first quarter after the first commercial sale of AKCEA-TTR-LRx occurs.

No definition available.

Name:	akca_PercentageOfProfitsAndLossesFromDevelopmentAndCommercializationOfDrug1RetainedTier2
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The percentage of profits and losses from the development and commercialization of AKCEA-TTR-L paid to Ionis.

No definition available.

Name:	akca_PercentageOfProfitsAndLossesFromDevelopmentAndCommercializationOfDrug2Paid
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The percentage of profits and losses from the development and commercialization of AKCEA-TTR-L retained by the Company.

No definition available.

Name:	akca_PercentageOfProfitsAndLossesFromDevelopmentAndCommercializationOfDrug2Retained
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The number of shares issued for the upfront licensing of TEGSEDI (inotersen) and AKCEA-TTR-L.

No definition available.

Name:	akca_SharesIssuedInConsiderationOfUpfrontLicensingFee
Namespace Prefix:	akca_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

The upfront licensing fee paid for the grant of rights under the License Agreement with Ionis Pharmaceuticals, Inc. (Ionis).

No definition available.

Name:	akca_UpfrontLicensingFeePaid
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

Name:	us-gaap_CommonStockSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Name:	us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_MinorityInterestLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The parent entity's interest in net assets of the subsidiary, expressed as a percentage.

No definition available.

Name:	us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

The cash inflow from the additional capital contribution to the entity.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Number of new stock issued during the period.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Name:	us-gaap_RelatedPartyTransactionAxis=akca_TTRDevelopmentCommercializationCollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=akca_IonisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=akca_InotersenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=akca_AKCEATTRLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=akca_InotersenAndAKCEATTRLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=akca_IonisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: